Administering AJOVY®

AJOVY® is the only licensed anti-CGRP that offers quarterly and monthly dosing.1

 

Flexibility to switch dosing regimens to suit your patients' needs

When switching dosing regimens, the first dose of the new regimen should be administered on the next scheduled dosing date of the prior regimen1

The treatment benefit should be assessed within three months after initiation of treatment. Evaluation of the need to continue treatment is recommended regularly thereafter.1

Suggestions to explore next

Continue to Efficacy page of AJOVY

Significantly more migraine-free days with AJOVY® vs placebo1-3

Clinical trial data for AJOVY®
Continue to Dosing flexibility page of AJOVY

Flexibility to help meet your patients' needs1

dosing options for ajovy®
Continue to Safety page of AJOVY

A generally well-tolerated treatment choice1-3

safety profile for ajovy®